The four rhythms above are each individually significant
The LEADER trial (liraglutide) and SUSTAIN-6 trial (semaglutide) both showed reductions in major adverse cardiac events in high-risk populations
GLP-1 medications are approved for adults who have a body mass index (BMI) of 30 or higher, or a BMI of at least 27 plus a weight-related medical condition, such as the following: Type 2 diabetes High blood pressure High cholesterol Obstructive sleep apnea Cardiovascular disease that increases the risk of heart attack or stroke MASH, or metabolic dysfunctionassociated steatohepatitis, a form of liver inflammation Avlin Imaeda, MD, PhD, a Yale Medicine gastroenterologist who is board-certified in obesity medicine, notes that qualifying for the medication based on heart disease aloneoften necessary for insurance coveragecan be challenging
Many people wonder: When should I increase my GLP-1 dose
These experiences motivated us to develop a safer, more natural, and more effective approach to metabolic health and weight management
